现代药物与临床
現代藥物與臨床
현대약물여림상
Drugs & Clinic
2015年
4期
404-408
,共5页
冠心舒通胶囊%急性心肌梗死%PCI术%高敏性C反应蛋白%血清淀粉样蛋白A
冠心舒通膠囊%急性心肌梗死%PCI術%高敏性C反應蛋白%血清澱粉樣蛋白A
관심서통효낭%급성심기경사%PCI술%고민성C반응단백%혈청정분양단백A
Guanxin Shutong Capsules%acute myocardial infarction%PCI%hs-CPR%SAA
目的:研究冠心舒通胶囊预防急性心肌梗死经皮冠状动脉介入治疗(PCI)术后再狭窄的临床疗效。方法选取2009年4月—2014年4月在西安医学院第二附属医院接受PCI手术的156例患者,随机分为对照组和治疗组,每组78例。对照组采用西药常规治疗,治疗组在对照组基础上加服冠心舒通胶囊,3粒/次,3次/d。两组均连续治疗6个月。观察两组患者心绞痛复发率,比较两组术前,治疗1、6个月时气虚血瘀证积分变化,同时比较两组患者高敏C反应蛋白(hs-CPR)和血清淀粉样蛋白A(SAA)的水平变化。结果对照组和治疗组心绞痛复发率分别为4.35%、17.65%,两组比较差异有统计学意义(P<0.05)。两组患者在治疗第1、6个月时肌酸激酶(CK)下降,在治疗第1个月时,治疗组CK低于对照组(P<0.05);治疗组气虚血瘀积分在治疗第1、6个月时显著下降且低于对照组,对照组在治疗第6个月时下降。与手术前相比,术后前3 d两组患者hs-CPR和SAA水平均明显升高(P<0.05);术后第7天开始下降,且术后7 d、1个月时治疗组hs-CPR和SAA水平显著低于对照组,两组比较差异有统计学意义(P<0.05)。结论冠心舒通胶囊对预防急性心肌梗死PCI术后再狭窄的发生有较好的疗效,可改善患者的气虚血瘀证,其作用机制可能是抑制血管内皮的炎症反应,改善心肌缺血。
目的:研究冠心舒通膠囊預防急性心肌梗死經皮冠狀動脈介入治療(PCI)術後再狹窄的臨床療效。方法選取2009年4月—2014年4月在西安醫學院第二附屬醫院接受PCI手術的156例患者,隨機分為對照組和治療組,每組78例。對照組採用西藥常規治療,治療組在對照組基礎上加服冠心舒通膠囊,3粒/次,3次/d。兩組均連續治療6箇月。觀察兩組患者心絞痛複髮率,比較兩組術前,治療1、6箇月時氣虛血瘀證積分變化,同時比較兩組患者高敏C反應蛋白(hs-CPR)和血清澱粉樣蛋白A(SAA)的水平變化。結果對照組和治療組心絞痛複髮率分彆為4.35%、17.65%,兩組比較差異有統計學意義(P<0.05)。兩組患者在治療第1、6箇月時肌痠激酶(CK)下降,在治療第1箇月時,治療組CK低于對照組(P<0.05);治療組氣虛血瘀積分在治療第1、6箇月時顯著下降且低于對照組,對照組在治療第6箇月時下降。與手術前相比,術後前3 d兩組患者hs-CPR和SAA水平均明顯升高(P<0.05);術後第7天開始下降,且術後7 d、1箇月時治療組hs-CPR和SAA水平顯著低于對照組,兩組比較差異有統計學意義(P<0.05)。結論冠心舒通膠囊對預防急性心肌梗死PCI術後再狹窄的髮生有較好的療效,可改善患者的氣虛血瘀證,其作用機製可能是抑製血管內皮的炎癥反應,改善心肌缺血。
목적:연구관심서통효낭예방급성심기경사경피관상동맥개입치료(PCI)술후재협착적림상료효。방법선취2009년4월—2014년4월재서안의학원제이부속의원접수PCI수술적156례환자,수궤분위대조조화치료조,매조78례。대조조채용서약상규치료,치료조재대조조기출상가복관심서통효낭,3립/차,3차/d。량조균련속치료6개월。관찰량조환자심교통복발솔,비교량조술전,치료1、6개월시기허혈어증적분변화,동시비교량조환자고민C반응단백(hs-CPR)화혈청정분양단백A(SAA)적수평변화。결과대조조화치료조심교통복발솔분별위4.35%、17.65%,량조비교차이유통계학의의(P<0.05)。량조환자재치료제1、6개월시기산격매(CK)하강,재치료제1개월시,치료조CK저우대조조(P<0.05);치료조기허혈어적분재치료제1、6개월시현저하강차저우대조조,대조조재치료제6개월시하강。여수술전상비,술후전3 d량조환자hs-CPR화SAA수평균명현승고(P<0.05);술후제7천개시하강,차술후7 d、1개월시치료조hs-CPR화SAA수평현저저우대조조,량조비교차이유통계학의의(P<0.05)。결론관심서통효낭대예방급성심기경사PCI술후재협착적발생유교호적료효,가개선환자적기허혈어증,기작용궤제가능시억제혈관내피적염증반응,개선심기결혈。
Objective To investigate the clinical effect of Guanxin Shutong Capsules in prevention of acute myocardial infarction with PCI postoperative restenosis.Methods The patients with acute myocardial infarction with PCI (156 cases) of the Second Affiliated Hospital of Xi’an Medical University from March 2009 to March 2014 were randomly divided into control and treatment groups, and each group had 78 cases. The patients in the control group were accepted routine western medicine. The patients in treatment group werepo administered with Guanxin Shutong Capsules, 3 grains/time, three times daily. Two groups were treated for six months. Angina recurrence rates in two groups were observed, and scores of Qixu Xueyu symptoms in two groups were compared before surgery and treatment of 1, 6 months. At the same time, the changes of hs-CPR and SAA were compared.Results The angina recurrence rates in the control and treatment groups were 4.35% and 17.65%, respectively, and there were differences between two groups (P< 0.05). The level of creatine kinase (CK) in the treatment fell in the treatment of first, sixth months, and CK was lower than that in the control group in the treatment of one month (P< 0.05). The score of Qixu Xueyu symptoms in the treatment group was reduced in the treatment of first, sixth months and lower than that in the control group (P< 0.05), while the score of Qixu Xueyu symptoms in the control group reduced in the treatment of sixth month. The levels of hs-CPR and SAA in two groups were significantly higher first three days after operation, while they declined from the seventh day after operation. And 7 d and one month after operation, the levels of hs-CPR and SAA in treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05).ConclusionGuanxin Shutong Capsules has the good clinical effect in prevention of acute myocardial infarction with PCI postoperative restenosis, and can improve Qixu Xueyu symptoms, while its mechanism may be inhibiting vascular endothelial inflammation and improve myocardial ischemia.